Inhibitor Therapeutics, Inc. (INTI)

OTCMKTS: INTI · Delayed Price · USD
-0.0025 (-5.16%)
Sep 27, 2022 4:00 PM EDT - Market closed
Market Cap 16.96M
Revenue (ttm) n/a
Net Income (ttm) -281,089
Shares Out 376.86M
EPS (ttm) 0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,643
Open 0.0450
Previous Close 0.0475
Day's Range 0.0450 - 0.0450
52-Week Range 0.0200 - 0.2000
Beta -0.63
Analysts n/a
Price Target n/a
Earnings Date n/a

About INTI

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed... [Read more...]

Industry Biotechnology
Founded 1992
CEO Nicholas Virca
Employees 1
Stock Exchange OTCMKTS
Ticker Symbol INTI
Full Company Profile


There is no news available yet.